RxDoctor Payments Data

Emily Davis

Physician Assistant · Manchester, CTNPI 1750785051

Payments from drug & device makers

$1,190in general payments, 2019–2025

Across 60 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$502
  • Dexcom, Inc.$184
  • Abbott$96
  • Amgen$82
  • Sanofi-aventis U.S. LLC$57
  • Cequr Corporation$48
  • plus $221 from 10 others

What the payments were for

  • Food & beverage$1,16097%
  • Other$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,190 in reported general payments places this provider in the 80th percentile of 1,795 physician assistant providers in Connecticut.

See all physician assistant providers in Connecticut

Medicare billing

Part B allowed, 2024
$20,256
Medicare patients
77
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide214$390,027
OzempicSemaglutide180$356,745
TrulicityDulaglutide72$134,406
JardianceEmpagliflozin77$104,567
Tresiba Flextouch U-200Insulin Degludec85$99,512
Humulin R U-500 KwikpenInsulin Regular, Human29$95,612
FarxigaDapagliflozin Propanediol71$83,062
JanuviaSitagliptin Phosphate50$56,430
ProliaDenosumab32$55,608
Tresiba Flextouch U-100Insulin Degludec75$45,660
InvokanaCanagliflozin23$36,339
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog42$35,388
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$27,300
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/722$25,247
Lantus SolostarInsulin Glargine,hum.Rec.Anlog183$24,353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$21$535,111323 claims
Novo NordiskOzempic$502$356,745180 claims
Boehringer IngelheimJardiance$29$104,56777 claims
AmgenProlia$82$55,60832 claims
Sanofi-aventis U.S. LLCLantus$57$3,55813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,795 physician assistant providers in Connecticut.

Other physician assistant in Manchester

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →